Literature DB >> 2570601

Assessment of airways, tremor and chronotropic responses to inhaled salbutamol in the quantification of beta 2-adrenoceptor blockade.

B J Lipworth1, R A Brown, D G McDevitt.   

Abstract

1. The purpose of the study was to assess and compare the effects of inhaled salbutamol on heart rate (HR), finger tremor (Tr) and specific airways conductance (sGaw) in the measurement of beta 2-adrenoceptor blockade in normal subjects. 2. Five healthy volunteers were given oral doses of atenolol 50 mg, 100 mg, 200 mg (A50, A100, A200), propranolol 40 mg (P40) or identical placebo (P1) in a single-blind crossover design. 3. Three hours after drug ingestion, dose-response curves were constructed using cumulative doses of inhaled salbutamol: 200 micrograms, 700 micrograms, 1700 micrograms, 3200 micrograms, 6200 micrograms. HR, Tr and sGaw were measured at each dose increment, made every 20 min. 4. Increasing doses of atenolol were associated with progressive reduction in salbutamol induced beta-adrenoceptor responses. The greatest attenuation occurred with propranolol. These effects on beta-adrenoceptor responses were similar for HR, Tr and sGaw. Geometric mean dose ratios (compared with placebo) for A50, A100, A200 and P40 were as follows HR: 1.98, 2.75, 4.29; Tr: 1.60, 3.78, 6.34, 80.50; sGaw: 1.08, 4.35, 12.30, 66.0 (no dose ratio was obtained for HR with P40). 5. These results showed that atenolol and propranolol attenuated the effects of salbutamol on HR to a similar degree as Tr and sGaw. Furthermore, the variability was least in the measurement of chronotropic responses, suggesting that this may be used to quantify beta 2-adrenoceptor antagonism. The beta 1-adrenoceptor selectivity of atenolol was a dose-dependent phenomenon, although the beta 2-adrenoceptor blockade of A200 was much less than with P40.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2570601      PMCID: PMC1379975          DOI: 10.1111/j.1365-2125.1989.tb03510.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  30 in total

1.  Comparison of effects of metoprolol and propranolol on asthmatic airway obstruction.

Authors:  C Skinner; J Gaddie; K N Palmer
Journal:  Br Med J       Date:  1976-02-28

2.  Comparison of the effects on airway conductance of a new selective beta-adrenergic blocking drug, atenolol, and propranolol in asthmatic subjects.

Authors:  H Aström
Journal:  Scand J Respir Dis       Date:  1975

3.  A comparison of four beta-adrenoceptor antagonists in patients with asthma.

Authors:  M K Benson; W T Berrill; J M Cruickshank; G S Sterling
Journal:  Br J Clin Pharmacol       Date:  1978-05       Impact factor: 4.335

Review 4.  The assessment of beta-adrenoceptor blocking drugs in man.

Authors:  D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1977-08       Impact factor: 4.335

5.  Effect of atenolol on ventilatory and cardiac function in asthma.

Authors:  J S Vilsvik; J Schaanning
Journal:  Br Med J       Date:  1976-08-21

6.  A standardized isoproterenol sensitivity test. The effects of sinus arrhythmia, atropine, and propranolol.

Authors:  C R Cleaveland; R E Rangno; D G Shand
Journal:  Arch Intern Med       Date:  1972-07

7.  Selective beta-1 receptor blockade with oral practolol in man. A dose-related phenomenon.

Authors:  J J Lertora; A L Mark; J Johannsen; W R Wilson; F M Abboud
Journal:  J Clin Invest       Date:  1975-09       Impact factor: 14.808

8.  Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker.

Authors:  H C Brown; S G Carruthers; G D Johnston; J G Kelly; J McAinsh; D G McDevitt; R G Shanks
Journal:  Clin Pharmacol Ther       Date:  1976-11       Impact factor: 6.875

9.  Human pharmacokinetic and pharmacodynamic studies on the atenolo (ICI 66,082), a new cardioselective beta-adrenoceptor blocking drug.

Authors:  F J Conway; J D Fitzgerald; J McAinsh; D J Rowlands; W T Simpson
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335

10.  Comparison of atenolol and oxprenolol in patients with angina or hypertension and co-existent chronic airways obstruction.

Authors:  W H Perks; S S Chatterjee; R S Croxson; J M Cruickshank
Journal:  Br J Clin Pharmacol       Date:  1978-02       Impact factor: 4.335

View more
  29 in total

1.  Selectivity of antagonist and partial agonist activity of celiprolol in normal subjects.

Authors:  N M Wheeldon; D G McDevitt; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

2.  Proceedings of the British Pharmacological Society, British Pharmacology Section. 18-20 April 1990, Sheffield. Abstracts.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

3.  Proceedings of the British Pharmacological Society. 12-14 September 1990, Belfast.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

4.  Comparison of hypokalaemic, electrocardiographic and haemodynamic responses to inhaled isoprenaline and salbutamol in young and elderly subjects.

Authors:  B J Lipworth; B F Tregaskis; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

5.  A dose-ranging study to evaluate the beta 1-adrenoceptor selectivity of bisoprolol.

Authors:  B J Lipworth; N A Irvine; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

6.  Evaluation of the beta 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol.

Authors:  A Grove; B J Lipworth
Journal:  Thorax       Date:  1996-01       Impact factor: 9.139

7.  The effects of chronic dosing on the beta 1 and beta 2-adrenoceptor antagonism of betaxolol and atenolol.

Authors:  B J Lipworth; N A Irvine; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

8.  Heart rate variability effects of an agonist or antagonists of the beta-adrenoceptor assessed with scatterplot and sequence analysis.

Authors:  B Silke; J G Riddell
Journal:  Clin Auton Res       Date:  1998-06       Impact factor: 4.435

Review 9.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

10.  Single dosing comparison of the relative cardiac beta 1/beta 2 activity of inhaled fenoterol and salbutamol in normal subjects.

Authors:  D M Newnham; N M Wheeldon; B J Lipworth; D G McDevitt
Journal:  Thorax       Date:  1993-06       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.